PDX Models - $167.6 Million Industry Business Expected in Basic Cancer Research
ID: 1746188
The global PDX models market is expected to reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of 16.7%.
(firmenpresse) - The key factors driving the growth of this market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. The growing use of humanized PDX models is posing a lucrative opportunity in this market.
According to a new market research report "Patient Derived Xenograft Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022", published by MarketsandMarkets™.
The market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%.
Don’t miss the opportunities in global PDX Models Market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
The various players in the PDX Models Market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
Browse and in-depth TOC on "Patient Derived Xenograft Models Market"
44 – Tables
34 – Figures
148 – Pages
By tumor type, the gastrointestinal tumor models segment accounted for the largest share of the market in 2017
On the basis of tumor type, the PDX Models Market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumors segment is expected to account for the largest share of the global PDx Models Market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
By application, the preclinical drug development and basic cancer research held the largest market share in 2017
Based on application, the PDx Models Market is further segmented into the preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDx Models Market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.
North America dominated the market in 2017
North America accounted for the largest share of the PDx Models Market in 2017, followed by Europe. The large share of the North American PDx Models Market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore.
Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Weitere Infos zu dieser Pressemeldung:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales(at)marketsandmarkets.com
![Erneut Auszeichnung von FOCUS MONEY \](/modules/PresseInfo/thump/fp_fwd.gif "Erneut Auszeichnung von FOCUS MONEY \")
Datum: 20.08.2019 - 12:26 Uhr
Sprache: Deutsch
News-ID 1746188
Anzahl Zeichen: 4104
Kontakt-Informationen:
Ansprechpartner: Dheeraj Shaha
Stadt:
Northbrook
Telefon: 18886006441
Kategorie:
Biotechnologie
Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 20.08.2015
Diese Pressemitteilung wurde bisher 619 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PDX Models - $167.6 Million Industry Business Expected in Basic Cancer Research"
steht unter der journalistisch-redaktionellen Verantwortung von
MnM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
The growth of this market is mainly driven by factors such as the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases. The report "Microplate Systems Market by Product (Microplate R
3D Cell Culture Market : Regenerative Medicine to Offer Global Growth In Coming Years ...
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private
Immuno Oncology Assays : Research Application Transforming the Industrial Business ...
What the Immuno Oncology Assays Market looks like? Growth in Immuno Oncology Assays Market is largely driven by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. According to the new market research report "Immuno Onco
Weitere Mitteilungen von MnM
Vink Chemicals erhöht die Produktionskapazität ...
Die Vink Chemicals GmbH & Co. KG hat kürzlich die ISP Biochema Schwaben GmbH in Memmingen (Bayern) übernommen. Diese Expansion erweitert die Produktionskapazität neben dem bereits bestehenden Produktionsstandort in Norddeutschland. Vink Chemicals erwirtschaftet rund 95 Prozent seines Umsatzes
Biosimulation Market to Register Substantial Expansion in Coming Years ...
The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, growing at a CAGR of 15.9%. Factors such as the increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, t
Conagen erweitert sein Gamma-Decalacton-Portfolio (y-Decalacton) auf 20 GMO-freie Lactone ...
Conagen, ein Biotechnologie-Unternehmen mit Sitz in Boston, das sich auf Forschung und Entwicklung konzentriert, gab heute seine mit firmeneigener Technologie erarbeitete bahnbrechende Entwicklung in der kommerziellen Produktion von natürlichen aromatischen ?-Decalacton-Verbindungen aus natürl
Glycomine, Inc. gibt Serie-B-Finanzierungüber 33 Millionen Dollar zur Weiterentwicklung seiner Therapie für angeborene Erkrankungen der Glykosylierung (Congenital Disease of Glycosylation) bekannt ...
Glycomine, Inc., ein Biotechnologieunternehmen, das auf die Entwicklung innovativer Therapien für seltene Erkrankungen spezialisiert ist, meldete heute, 33 Millionen Dollar im Rahmen einer Finanzierungsrunde (Serie B) unter der Führung von Novo Holdings A/S beschafft zu haben. Mit dem Finanzi
